Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avellutolimab with Short-Cycle Chemotherapy in Early-Stage TNBC
NCT07178171Phase 1Recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iparomlimab + tuvonralimab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response Rate. Started Nov 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07178171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178171.